Maastricht 2017 Meeting Highlights Registration Programme Overview Exhibition Virtual Exhibition Hotels Satellite Meetings Visa Letter Application Star Alliance Travel Discount
title

10 - 12 February 2017, MECC Maastricht,The Netherlands.

This Meeting has been awarded 15 CME credits.

Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Multicenter evaluation of patients bilaterally implanted with the Tecnis toric 1-piece intraocular lens

Poster Details


First Author: M. Khan CANADA

Co Author(s): I. Ahmed                    

Abstract Details

Purpose:

To evaluate the efficacy, stability, predictability, and patient-reported outcomes following bilateral implantation of the Tecnis toric 1-piece intraocular lens.

Setting:

Ten clinical sites across Canada.

Methods:

In this study, 77 patients were bilaterally implanted with the Tecnis toric 1-piece IOL.  Binocular uncorrected distance visual acuity (UDVA), manifest refraction, and IOL rotational stability were assessed at 1-month and 3-months postoperatively. A patient questionnaire on spectacle independence, visual disturbances, and satisfaction with vision at baseline, 1-month, and 3-months postoperatively was conducted. A physician survey was also conducted to assess ease of use and surgeons’ overall evaluation of the lens.

Results:

The study included 77 patients (154 eyes). At 3-months post-implant, the binocular UCVA was 20/20 or better in 71% of patients and 20/40 or better in 99% of patients, which represented a significant improvement from baseline (p<0.001). The mean residual refractive astigmatism was 0.58 D (± 0.45). IOL alignment was within ±5 degrees in 87% of eyes and within ±10 degrees in 94% of eyes. Eighty percent of patients never used distance spectacles or contacts after surgery. Frequency and severity of glare and haloes significantly reduced from pre- to post-op. Satisfaction with vision was rated “satisfied” or better by 92%.

Conclusions:

Bilateral implantation with the Tecnis® Toric IOL is an effective means of treating corneal astigmatism, with a statistically significant reduction in refractive astigmatism and improvement in UDVA, as well as high patient satisfaction rates.

Financial Disclosure:

None

Back to Poster listing